Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drug Metabolism And Disposition

• Publication date

  2008-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.108.020834PMID 18411401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations

  2008influential reference
• Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

  2007cited by this paper
• Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction

  2007influential reference
• Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination

  2007cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007cited by this paper
• BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT

  2006cited by this paper
• Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

  2006cited by this paper
• EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES

  2006cited by this paper
• DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1

  2006cited by this paper
• THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES

  2005cited by this paper
• Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches

  2004cited by this paper
• The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.

  2002cited by this paper
• The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations.

  1996cited by this paper

• Applying high throughput toxicokinetics (HTTK) to per- and polyfluoro alkyl substances (PFAS)

  2026cites this paper
• Hepatic and Extra-Hepatic Metabolism of Propylene Glycol Ethers in the Context of Central Nervous System Toxicity.

  2025cites this paper
• Applying New Approach Methods for Toxicokinetics for Chemical Risk Assessment.

  2025cites this paper
• Estimation of In Vivo Half‐Life From In Vitro Metabolic Clearance, Protein, and Cell Membrane Affinity Assays

  2025cites this paper
• Optimization of In Vitro CYP3A4 TDI Assay Conditions and Use of Derived Parameters for Clinical DDI Risk Assessment Using Static and Dynamic Models

  2025cites this paper
• AOP-informed qIVIVE modelling for liver steatosis using triazoles

  2025cites this paper
• Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance.

  2025cites this paper
• Mechanistic in vitro–in vivo extrapolation (IVIVE) approach using a biomimetic in vitro system for the prediction of hepatic clearance

  2025cites this paper
• Discovery of Pre-Clinical Candidate VU6008055/AF98943: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy

  2025cites this paper
• Improving the predictivity of human maximum plasma concentrations for soybean isoflavones and glucosides using an improved culture method of human induced pluripotent stem cell-derived small intestinal epithelial cells.

  2025cites this paper
• In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space.

  2025cites this paper
• Interpretation of thyroid-relevant bioactivity data for comparison to in vivo exposures: A prioritization approach for putative chemical inhibitors of in vitro deiodinase activity.

  2025cites this paper
• Enabling transparent toxicokinetic modeling for public health risk assessment

  2025cites this paper
• Beyond-Rule-of-Five Compounds Are Not Different: In Vitro–In Vivo Extrapolation of Female CD-1 Mouse Clearance Based on Merck Healthcare KGaA Compound Set

  2025influential citation
• In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©.

  2025influential citation
• Discovery of Potent and Brain-Penetrant Bicyclic NLRP3 Inhibitors with Peripheral and Central In Vivo Activity.

  2025cites this paper
• Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders

  2025cites this paper
• Comparison of Human Long-Term Liver Models for Clearance Prediction of Slowly Metabolized Compounds

  2024influential citation
• Comparison of commonly used and new methods to determine small molecule non-specific binding to human liver microsomes.

  2024cites this paper
• Mechanobiological stimulation in organ‐on‐a‐chip systems reduces hepatic drug metabolic capacity in favor of regenerative specialization

  2024cites this paper
• Aminobenzotriazole inhibits and induces several key drug metabolizing enzymes complicating its utility as a pan CYP inhibitor for reaction phenotyping

  2024cites this paper
• Inhibition of Neural Crest Cell Migration by Strobilurin Fungicides and Other Mitochondrial Toxicants

  2024cites this paper
• Clearance prediction with three novel plated human hepatocyte models compared to conventional suspension assays: Assessment with 50 compounds and multiple donors.

  2024cites this paper
• In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From β‐Isomer Propylene Glycol Methyl Ether

  2024influential citation
• Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates

  2024cites this paper
• Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment.

  2024cites this paper
• Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation

  2024cites this paper
• How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data

  2024cites this paper
• Proof of Concept of an All-in-One System for Measuring Hepatic Influx, Egress, and Metabolic Clearance Based on the Extended Clearance Concept

  2024cites this paper
• Predicting the Intravenous Pharmacokinetics of Covalent Drugs in Animals and Humans.

  2024cites this paper
• Human Pharmacokinetic and CYP3A Drug–Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment

  2024cites this paper
• In vitro and in vivo studies on the metabolism and pharmacokinetics of the selective gut microbial β-glucuronidase targeting compound Inh 1

  2024cites this paper
• Evaluation and Optimization of a Microcavity Plate–Based Human Hepatocyte Spheroid Model for Predicting Clearance of Slowly Metabolized Drug Candidates

  2024cites this paper
• From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling

  2024cites this paper
• HLM chip - A microfluidic approach to study the mechanistic basis of cytochrome P450 inhibition using immobilized human liver microsomes.

  2024cites this paper
• In vitro-based prediction of human plasma concentrations of food-related compounds.

  2023cites this paper
• DNDI-6174, a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1 complex

  2023cites this paper
• Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib

  2023cites this paper
• Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4‐Conjugate), Based on an In Vitro–In Vivo Extrapolation Approach

  2023cites this paper
• In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis

  2023cites this paper
• The Politics of Using AI in Public Policy: Experimental Evidence

  2023cites this paper
• Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation

  2023cites this paper
• Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

  2023cites this paper
• Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders.

  2023cites this paper
• Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review

  2023influential citation
• Simplifying the Extended Clearance Concept Classification System (EC3S) to Guide Clearance Prediction in Drug Discovery

  2023cites this paper
• Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration

  2023cites this paper
• EFSA Pilot Project on New Approach Methodologies (NAMs) for Tebufenpyrad Risk Assessment. Part 1. Development of Physiologically‐Based Kinetic (PBK) Model Coupled With Pulmonary and Dermal Exposure

  2023cites this paper
• The impact of reference data selection for the prediction accuracy of intrinsic hepatic metabolic clearance.

  2022cites this paper
• Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl1

  2022cites this paper
• Multi-Well Array Culture of Primary Human Hepatocyte Spheroids for Clearance Extrapolation of Slowly Metabolized Compounds

  2022cites this paper
• Analysis of Time-Dependent Pharmacokinetics Using In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling

  2022influential citation
• Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma

  2022cites this paper
• Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

  2022cites this paper
• The in vitro metabolism and in vivo pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652

  2022cites this paper
• Predictive Performance of Next Generation Human Physiologically Based Kinetic (PBK) Models Based on In Vitro and In Silico Input Data

  2022cites this paper
• SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp® simulator

  2022influential citation
• LipMetE (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral Drugs.

  2022cites this paper
• Characterisation of intravenous pharmacokinetics in Göttingen minipig and clearance prediction using established in vitro to in vivo extrapolation methodologies

  2022cites this paper
• Effective exposure of chemicals in in vitro cell systems: A review of chemical distribution models.

  2021cites this paper
• Predictive Performance of Next Generation Physiologically Based Kinetic (PBK) Model Predictions in Rats Based on In Vitro and In Silico Input Data

  2021cites this paper
• Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model

  2021cites this paper
• In Vitro ADME Assays and In Vivo Extrapolations

  2021cites this paper
• Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450

  2021cites this paper
• Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

  2021cites this paper
• Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast.

  2021cites this paper
• Predicting human pharmacokinetics from preclinical data: clearance

  2021cites this paper
• Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes

  2021cites this paper
• High-throughput PBTK models for in vitro to in vivo extrapolation

  2021cites this paper
• Evaluation and comparison of in vitro intrinsic clearance rates measured using cryopreserved hepatocytes from humans, rats, and rainbow trout.

  2021cites this paper
• Designing QSARs for Parameters of High-Throughput Toxicokinetic Models Using Open-Source Descriptors.

  2021cites this paper
• GUIDANCE DOCUMENT ON THE CHARACTERISATION, VALIDATION AND REPORTING OF PBK MODELS FOR REGULATORY PURPOSES

  2021cites this paper
• Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization.

  2021cites this paper
• A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market

  2021cites this paper
• Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

  2020cites this paper
• Kinetics of metabolism of deltamethrin and cis- and trans-permethrin in vitro. Studies using rat and human liver microsomes, isolated rat hepatocytes and rat liver cytosol

  2020cites this paper
• Development of a Web-Based Toolbox to Support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within Nonanimal Testing Strategies

  2020cites this paper
• Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery

  2019cites this paper
• Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization.

  2019cites this paper
• Quantitative in vitro-to-in vivo extrapolation (QIVIVE) of estrogenic and anti-androgenic potencies of BPA and BADGE analogues

  2019cites this paper
• A Cell-Free Approach Based on Phospholipid Characterization for Determination of the Cell Specific Unbound Drug Fraction (fu,cell)

  2019cites this paper
• Towards harmonization of test methods for in vitro hepatic clearance studies.

  2019cites this paper
• Characterization of parameters influencing intracellular bioavailability and prediction of intracellular drug exposure

  2019cites this paper
• Prediction of fraction unbound in microsomal and hepatocyte incubations - a comparison of methods across industry datasets.

  2019cites this paper
• REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

  2019cites this paper
• Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10

  2019cites this paper
• Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies

  2019cites this paper
• Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions

  2019cites this paper
• An examination of protein binding and protein‐facilitated uptake relating to in vitro‐in vivo extrapolation

  2018cites this paper
• Importance of the Unstirred Water Layer and Hepatocyte Membrane Integrity In Vitro for Quantification of Intrinsic Metabolic Clearance

  2018cites this paper
• Biophysical methods: Complementary tools to study the influence of human steroid hormones on the liposome membrane properties.

  2018cites this paper
• Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.

  2018cites this paper
• Development and Characterization of a Human Hepatocyte Low Intrinsic Clearance Assay for Use in Drug Discovery

  2018cites this paper
• Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.

  2018cites this paper
• Evaluation and Optimization of Pharmacokinetic Models for in Vitro to in Vivo Extrapolation of Estrogenic Activity for Environmental Chemicals

  2018cites this paper
• Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example

  2018cites this paper
• Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions

  2018influential citation
• In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds

  2018cites this paper
• Prediction of renal transporter‐mediated drug‐drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling

  2017cites this paper
• Intrinsic Clearance Assay Incubational Binding: A Method Comparison

  2017influential citation